Drug interactions
Secukinumab + Ublituximab
Severity: Moderate
Secukinumab and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells, and combining it with secukinumab may add to immunosuppression and the risk of infection. Combined use is uncommon and not well studied.
What this interaction means in plain words
Secukinumab and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Secukinumab belongs to Miscellaneous; Ublituximab belongs to Miscellaneous.
Why it happens
Additive immunosuppression from B-cell depletion (anti-CD20) and IL-17A inhibition.
What to do
Screen for active infection before dosing and monitor for infections during co-therapy. Reassess the need for both agents.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Secukinumab and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Secukinumab
- Adenovirus types 4 and 7 live + Secukinumab Major
- Bcg vaccine live + Secukinumab Major
- Influenza virus vaccine quadrivalent intranasal + Secukinumab Major
- Measles mumps and rubella vaccine live + Secukinumab Major
- Measles mumps and rubella vaccine + Secukinumab Major
- Measles mumps rubella and varicella vaccine live + Secukinumab Major
Other interactions of Ublituximab
Frequently asked questions
Can I take Secukinumab with Ublituximab?
MediHelp rates the interaction as moderate. Secukinumab and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ublituximab depletes B cells, and combining it with secukinumab may add to immunosuppression and the risk of infection. Combined use is uncommon and not well studied.
How serious is the interaction between Secukinumab and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Screen for active infection before dosing and monitor for infections during co-therapy. Reassess the need for both agents.
What other medicines interact with Secukinumab?
MediHelp also lists interactions of Secukinumab with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal. The full list is on the Secukinumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
